331-345 of 360
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CEUnlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CEUnlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CEUnlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD
Pasi Antero Jänne, MD, PhD
Advances in Minimally Invasive Screening for Lung Cancer
CME/CEAdvances in Minimally Invasive Screening for Lung Cancer
Julie A. Barta, MD, ATSF
Peter J. Mazzone, MD, MPH, FCCP
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
CME/CETreatment Options for Invasive Fungal Infections: Why They Don't Always Work
Thomas F. Patterson, MD, FACP, FIDSA
George Thompson III, MD, FIDSA
Invasive Fungal Infections: More Common Than You Think
CME/CEInvasive Fungal Infections: More Common Than You Think
Peter G. Pappas, MD, FACP
Thomas F. Patterson, MD, FACP, FIDSA
- advertisement
Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
CME/CEExpert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
Mark Socinski, MD
Patrick Forde, M.B.B.Ch.
Karen Reckamp, MS, MD
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
CME/CECurrent Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
CME/CECurrent and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
Mamta Parikh, MD, MS
Daniel P. Petrylak, MD
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CEUtilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
William J. Gradishar, MD
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CETROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Benjamin Levy, MD
Rebecca Heist, MD, MPH
Peter Bela Illei, MD
Improved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
CME/CEImproved Outcomes in mCRPC with PSMA-Directed Diagnostics and Therapies
Ayse Tuba Kendi, MD
A. Oliver Sartor, MD
- advertisement
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
CME/CEEvolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
William Mencia, MD, FACEHP
Julie Blatt, MD
Taizo Nakano, MD
Jaffer Ajani, MD
Justin Gainor, MD
Sara A. Hurvitz, MD, FACP
Gopa Iyer, MD
Sara A. Hurvitz, MD, FACP
